Bordet Scientific Publications Bordet Scientific Publications Search… Année de publication - Any -20242025 Management of high-grade neuroendocrine neoplasms: impact of functional imaging. Auteurs Islam O, Sarti K, Verbruggen L, Vandermissen V, Vanden Bulcke K, Annys L, Verslype C, Van Laethem JL, Kalantari HR, Janssens J, Hendlisz A, Cuyle PJ, Demolin G, Decaestecker J, Geboes K, Coche JL, Van Ongeval J, Lybaert W, Peeters M, Borbath I, Vandamme T Auteurs (entité) HENDLISZ ALAIN Revue Endocr Relat Cancer Date de publication 2025-01 Management of high-grade neuroendocrine neoplasms: impact of functional imaging. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial. Auteurs Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano de Colella JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hébraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Cherel B, Frenzel L, Vekemans MM, Bigot N, Avet-Loiseau H, Corre J, Moreau P Auteurs (entité) MEULEMAN NATHALIE Revue Blood Date de publication 2025-01 Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial. Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. Auteurs Mouna O, Hanssens C, Meyers M, Langouo M Auteurs (entité) LANGOUO FONTSA MIREILLE Revue Curr Opin Oncol Date de publication 2025-01 Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. Auteurs Mouna O, Hanssens C, Meyers M, Langouo M Auteurs (entité) MOUNA Oumnia Revue Curr Opin Oncol Date de publication 2025-01 Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. Auteurs Mouna O, Hanssens C, Meyers M, Langouo M Auteurs (entité) MEYERS MICHEL Revue Curr Opin Oncol Date de publication 2025-01 Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Auteurs Meyers M, Mouna O, Langouo M Auteurs (entité) MEYERS MICHEL Revue Curr Opin Oncol Date de publication 2024-12 Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Auteurs Meyers M, Mouna O, Langouo M Auteurs (entité) LANGOUO FONTSA MIREILLE Revue Curr Opin Oncol Date de publication 2024-12 Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Auteurs Meyers M, Mouna O, Langouo M Auteurs (entité) MOUNA Oumnia Revue Curr Opin Oncol Date de publication 2024-12 Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Macroscopic Hematuria Revealing Bladder Myeloid Sarcoma in Acute Myeloid Leukemia. Auteurs Halloumi O, Sebastian W, Harb M, Trépant AL, Andreozzi F Auteurs (entité) ANDREOZZI FABIO Revue Cureus Date de publication 2024-12 Macroscopic Hematuria Revealing Bladder Myeloid Sarcoma in Acute Myeloid Leukemia. Load More Erasmus Hospital View all of Erasmus's scientific publications Erasmus's academic publications Queen Fabiola Children's Hospital View all scientific publications from the Queen Fabiola Children's Hospital Scientific publications from the Queen Fabiola Children's Hospital Jules Bordet Institute View all of Jules Bordet's scientific publications Scientific publications by Jules Bordet
Management of high-grade neuroendocrine neoplasms: impact of functional imaging. Auteurs Islam O, Sarti K, Verbruggen L, Vandermissen V, Vanden Bulcke K, Annys L, Verslype C, Van Laethem JL, Kalantari HR, Janssens J, Hendlisz A, Cuyle PJ, Demolin G, Decaestecker J, Geboes K, Coche JL, Van Ongeval J, Lybaert W, Peeters M, Borbath I, Vandamme T Auteurs (entité) HENDLISZ ALAIN Revue Endocr Relat Cancer Date de publication 2025-01 Management of high-grade neuroendocrine neoplasms: impact of functional imaging.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial. Auteurs Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano de Colella JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hébraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Cherel B, Frenzel L, Vekemans MM, Bigot N, Avet-Loiseau H, Corre J, Moreau P Auteurs (entité) MEULEMAN NATHALIE Revue Blood Date de publication 2025-01 Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial.
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. Auteurs Mouna O, Hanssens C, Meyers M, Langouo M Auteurs (entité) LANGOUO FONTSA MIREILLE Revue Curr Opin Oncol Date de publication 2025-01 Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy.
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. Auteurs Mouna O, Hanssens C, Meyers M, Langouo M Auteurs (entité) MOUNA Oumnia Revue Curr Opin Oncol Date de publication 2025-01 Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy.
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy. Auteurs Mouna O, Hanssens C, Meyers M, Langouo M Auteurs (entité) MEYERS MICHEL Revue Curr Opin Oncol Date de publication 2025-01 Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy.
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Auteurs Meyers M, Mouna O, Langouo M Auteurs (entité) MEYERS MICHEL Revue Curr Opin Oncol Date de publication 2024-12 Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Auteurs Meyers M, Mouna O, Langouo M Auteurs (entité) LANGOUO FONTSA MIREILLE Revue Curr Opin Oncol Date de publication 2024-12 Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Auteurs Meyers M, Mouna O, Langouo M Auteurs (entité) MOUNA Oumnia Revue Curr Opin Oncol Date de publication 2024-12 Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?
Macroscopic Hematuria Revealing Bladder Myeloid Sarcoma in Acute Myeloid Leukemia. Auteurs Halloumi O, Sebastian W, Harb M, Trépant AL, Andreozzi F Auteurs (entité) ANDREOZZI FABIO Revue Cureus Date de publication 2024-12 Macroscopic Hematuria Revealing Bladder Myeloid Sarcoma in Acute Myeloid Leukemia.
Queen Fabiola Children's Hospital View all scientific publications from the Queen Fabiola Children's Hospital Scientific publications from the Queen Fabiola Children's Hospital
Jules Bordet Institute View all of Jules Bordet's scientific publications Scientific publications by Jules Bordet
